Aclaris Therapeutics announced positive phase 1b proof-of-concept results for ATI-052, an investigational bispecific antibody ...

Patients on Medicare often do everything insurers ask, including trying and failing the standard topicals, and still can’t ...

Experts outline how to recognize undertreated psoriasis, assess incomplete response, and make individualized decisions when escalating therapy. The treatment landscape for psoriasis has changed ...

Asked what single change would most improve identification and escalation of uncontrolled HS, Dr. Bush urges clinicians not to be apprehensive about treating the disease or using ...

Treatment success in alopecia areata extends beyond a SALT score. Dr. Ungar reviews patient-reported outcome data and describes how he sets timelines for judging response and deciding when to switch.

Christopher Bunick, MD, PhD, reviews data on investigational atopic dermatitis agents presented at EADV 2026 and biomarker findings for upadacitinib. Falk G. Bechara, MD, discusses long-term tunnel ...

Houston dermatology clinicians compared severity scoring, JAK inhibitor safety data, and psychosocial counseling strategies across 3 alopecia areata patient cases. Shannon Trotter, DO, moderated a ...

On this episode of Don’t Be Rash, host Andrew C. Krakowski, MD, welcomes Lawrence Eichenfield, MD, pediatric dermatologist, to discuss topical corticosteroid potency, dosing, and where they fit ...

Aldredge called Horizons in Advanced Practice one of the most profound meetings for newer dermatology NPs and PAs. The intimate audience setting gives attendees access to updated, evidence-based ...

One of the most common misconceptions Feldman encounters among patients and caregivers is that eczema is simply a problem of ...

Oral JAK inhibitors are preferred first-line long-term therapy for severe adult AA; FDA-approved agents are favored, whereas dupilumab is an alternative for patients with comorbid atopy. Experts ...

The FDA has accepted Lynch Regenerative Medicine’s (LRM) investigational new drug (IND) application for a phase 2b clinical ...